Top Abstract Purchase Preview Related
Home
>
Node
>
Subnode

Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group

Taguchi, T.; Koyama, H.; Yayoi, K.; Wada, T.; Takatsuka, Y.; Sonoo, H.; Morimoto, K.; Tominaga, T.; Abe, R.; Enomoto, K.

Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(4): 495-508

1995

ISSN/ISBN: 0385-0684
PMID: 7887641
Document Number: 7093
Efficacy and safety of long-term treatment with an LH-RH agonist, TAP-144-SR were studied in premenopausal patients with advanced or recurrent breast cancer. The drug was given sc every 4 week at the dose of 3.75 or 7.5mg. The best objective response rates were 37.0% (17/46) in 3.75mg group, 30.6% (15/49) in 7.5mg group, respectively. The median duration of 12 PR patients in 3.75mg group was 280 (range: 84-830+) days. Serum estradiol level was maintained at < 30pg/ml in most patients given 3.75mg or 7.5mg as scheduled. There was no adverse reactions specific to the longterm administration subsequent to the foregoing 12-week administration study in both dose groups. In conclusion, TAP-144-SR is expected to be one of the first line therapies for patients with premenopausal breast cancer.

Document emailed within 1 workday
Secure & encrypted payments

Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group

Okawa, T.; Ikeda, M.; Mikuriya, S.; Hashimoto, S.; Amino, S.; Horiuchi, J.; Matsuda, T.; Ebata, K.; Kaneda, K. 1985: A clinical study of radiotherapy with HCFU for advanced and recurrent breast cancers. Radiation and HCFU Study Group for breast cancer Gan no Rinsho. Japan Journal of Cancer Clinics 31(2): 131-136
Tominaga, T.; Nomura, Y.; Adachi, I.; Aoyama, H.; Nagao, K.; Mitsuyama, S.; Nakamura, Y.; Ogita, M.; Sano, M.; Takashima, S. 1994: Late phase II study of KW-2307 in advanced or recurrent breast cancer. KW-2307 Cooperative Study Group (Breast Cancer Section) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(6): 809-816
Taguchi, T.; Mori, S.; Abe, R.; Hasegawa, K.; Morishita, Y.; Tabei, T.; Sasaki, Y.; Fujita, M.; Enomoto, K.; Hamano, K. 1994: Late phase Ii clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(15): 2625-2632
Castiglione-Gertsch, M.; Tattersall, M.; Hacking, A.; Goldhirsch, A.; Gudgeon, A.; Gelber, R.D.; Lindtner, J.; Coates, A.; Collins, J.; Isley, M.; Senn, H.J.; Rudenstam, C.M. 1997: Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group European Journal of Cancer 33(14): 2321-2325
Lawson, D.; Moore, M.; Smalley, R. 1980: An evaluation of hexamethylmelamine, cis-diamminedichloroplatinum, and mitomycin-C in advanced breast cancer. a pilot study of the Southeastern Cancer Study Group Cancer Clinical Trials 3(4): 293-296
Crivellari, D. 2002: Results of adjuvant treatments in breast cancer patients over 70 years old: the IBCSG experience. International Breast Cancer Study Group Tumori 88(1 Suppl. 1): S81-S82
Salvadori, B.; Celio, L.; Oriana, R.; Bajetta, E. 2000: Adjuvant oophorectomy versus CMF in premenopausal node-positive breast cancer: long-term results of an experience at the Milan Cancer Institute Tumori 86(3): 258-259
Tominaga, T.; Abe, O.; Izuo, M.; Isono, K.; Enomoto, K.; Nishi, M.; Fukami, A.; Muto, T.; Morioka, Y.; Watanabe, H. 1993: Correlations between estrogen receptor and prognostic factors of patients with breast cancer. the Kanto Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(14): 2171-2176
Levin, M.; Pandya, K.J.; Khandekar, J.D.; Horton, J.; Glick, J.H.; Bennett, J.M.; Muggia, F.M.; Falkson, G. 1984: Phase Ii study of mitoxantrone in advanced breast cancer: an Eastern Cooperative Oncology Group pilot study Cancer Treatment Reports 68(12): 1511-1512
de Graaf, H.; Willemse, P.H.; Sleijfer, D.T.; de Vries, E.G.; Van der Graaf, W.T.; Beukema, J.; Mulder, N.H. 1994: Effective conditioning regimen for premenopausal patients with advanced breast cancer Anticancer Research 14(6b): 2799-2804
Wada, Y.; Otoshi, M.; Jitsuko, A.; Nishikawa, H.; Takahara, S.; Tsubono, M.; Imai, S. 2007: A phase Ii study of weekly paclitaxel for advanced or recurrent breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(7): 1041-1045
Amrein, P.C.; Coleman, M.; Richards, F.; Poulin, R.F.; Bernhardt, B.; Ginsberg, S.J.; Green, M.R.; Morrison, A.; Cortes, E.; Kiang, D.; Weinberg, V.; Wood, W.C. 1982: Phase Ii study of AMSA in patients with metastatic breast cancer: a Cancer and Leukemia Group B study Cancer Treatment Reports 66(5): 1211-1213
Fortunato, L.; Drago, S.; Vitelli, C.E.; Santoni, M.; Gucciardo, G.; Cabassi, A.; Farina, M.; La Pinta, M.; Remedi, M.; Pagano, G.; Silipod, T.; Terribile, D.; Stagnitto, D.; Grassi, G.B. 2006: Sentinel lymph node biopsy in breast cancer. Experience of the Rome Breast Cancer Study Group Chirurgia Italiana 58(6): 689-696
Bhatavdekar, J.M.; Shah, N.G.; Patel, D.D.; Karelia, N.H.; Trivedi, S.N.; Vora, H.H.; Ghosh, N.; Giri, D.D.; Balar, D.B. 1992: Endocrine function in premenopausal and postmenopausal advanced breast cancer patients treated with CMF or tamoxifen Neoplasma 39(2): 123-127
Samal, B.; Jones, S.; Brownlee, R.W.; Morrison, F.; Hoogstraten, B.; Caoili, E.; Baker, L. 1978: Chromomycin A3 for advanced breast cancer: a Southwest Oncology Group study Cancer Treatment Reports 62(1): 19-22
2006: Comparative effects of the administration period of adjuvant chemotherapy using doxifluridine (5'-DFUR) for 1 year versus 3 years after breast cancer surgery by the Shimane Breast Cancer Study Group Anticancer Research 26(1b): 591-597
Mitsuyama, S.; Kuroda, Y.; Ohsato, K.; Nakamura, Y.; Murakami, F.; Nishikata, F.; Ikeda, S.; Egami, T.; Mori, A.; Ohe, H. 1996: Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(9): 1153-1160
Sugihara, K.; Auther, C.; Mori, S.; Nishihira, T.; Matsumoto, T.; Kawachi, S.; Ishikawa, M.; Takahashi, M.; Nakajima, T.; Kosaki, G. 1990: Early phase Ii study of the combined use of AO-90 methionine-free amino acid solution and anticancer agents (5-FU and MMC) in patients with advanced and recurrent gastrointestinal cancer. AO-90 Study group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 17(12): 2405-2413
Sajjinanont, T.; Rajchadara, S.; Sriassawaamorn, N.; Panichkul, S. 2005: The comparative study of bone mineral density between premenopausal women receiving long term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women Journal of the Medical Association of Thailand 88(Suppl 3): S71-S76
Albeshan, S.M.; Hossain, S.Z.; Mackey, M.G.; Brennan, P.C. 2020: Can Breast Self-examination and Clinical Breast Examination Along with Increasing Breast Awareness Facilitate Earlier Detection of Breast Cancer in Populations with Advanced Stages at Diagnosis? Clinical Breast Cancer 20(3): 194-200